Navigation Links
UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
Date:8/6/2013

NEW YORK, Aug. 6, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Columbia on behalf of investors who purchased Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (NasdaqGM: VNDA) stock between December 18, 2012 and June 18, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

For more information, click here: http://zlk.9nl.com/vanda-pharmaceuticals-vnda/

The complaint alleges that defendants violated federal securities laws by issuing materially false and misleading statements and/or failing to disclose materially adverse facts concerning the Company's Phase III testing of the drug Tasimelteon. In particular, it is alleged that, in the middle of the Phase III studies, Vanda altered the primary endpoint to one never before used in a sleep-drug clinical trial—and not endorsed by the FDA—when data suggested the original endpoint would not be met.

On June 19, 2013, an article was published on thestreet.com, questioning the efficacy of Vanda's study, noting that the study not only changed multiple times, but that it replaced the primary endpoint just a month before study results were announced. On the news, shares of Vanda closed at $8.51 per share on June 19, 2013, a drop of more than 20% from the previous day.

If you suffered a loss in Vanda you have until August 24, 2013 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone
'/>"/>

SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
2. Hospira to Present at Upcoming Investor Conferences
3. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
4. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
7. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
8. MDHI Provides Investor Update -- Provides Business Model Overview -- Discusses Upcoming Profitability
9. Delcath To Present At Upcoming Investor Conferences
10. Uroplasty To Participate In Two Upcoming Conferences
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 According to a ... Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), ... (AF, VT, WPW) - Global Forecasts to 2019 ", published ... reach around ~$4.73 Billion by 2019 with a CAGR ... 2019. Browse   90   ma ...
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
(Date:3/27/2015)... 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... today announced that they have entered into ... and proprietary sd-rxRNA® technology for use in ... has the potential to result in novel, ... that could be a significant step toward ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... pirfenidone may provide meaningful clinical benefit in IPF patients ... reported -- Conference Call and Webcast at 9 p.m. ... InterMune, Inc. (Nasdaq: ITMN ) reported ... evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) ...
... 19 New data demonstrate that maintenance therapy with ... time to relapse compared to placebo in patients with ... this week at a major medical meeting. Bipolar ... in a person,s mood, energy and ability to function. ...
Cached Medicine Technology:Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
(Date:3/27/2015)... Alberta (PRWEB) March 27, 2015 In her ... then, prevented her from working, Monica K. arrived at ... the mending department quiet, defensive and scared. The owners and ... & Support Services (EPSS) to offer jobs to challenged ... take patience and a willingness to begin with the end ...
(Date:3/27/2015)... March 27, 2015 First Choice Emergency ... The new facility is located 12665 W Lake Houston Pkwy, ... resident of Summerwood, I look forward to delivering the highest ... Sowell, Facility Medical Director of First Choice Emergency Room Summerwood. ... Room made a donation to Summer Creek High School at ...
(Date:3/27/2015)... Healthpointe is proud to announce that ... now treating knee and hip joint disorders in practice ... Beach, and La Mirada. Dr. Stanley Katz specializes in ... joint disorders as well as chronic conditions such as ... his patients back to their normal lives. Many ...
(Date:3/27/2015)... 2015 The report “CountryFocus Healthcare, ... essential source of information on and analysis of ... Germany’s increasingly elderly population and its associated disease ... In 2013, the elderly accounted for 27.1% of ... Annual Growth Rate (CAGR) of 1.2% to 29.5% ...
(Date:3/27/2015)... According to a recently published report series ... screw market in Europe is in decline due to ... segment. Price decreases are being seen across the entire ... the total European trauma device market, continued pricing pressure ... year after year. , “Such price drops are ...
Breaking Medicine News(10 mins):Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3
... geneticist at the University of Edinburgh, Scotland, had announced on ... called Uqcrc1 in the brains of mouse used as models ... powerhouses of the cells to work overtime. Dr. Bird stated ... been linked to Rett Syndrome. The co-author of the study ...
... that the male survivors of childhood sexual abuse ... understood// many health care practitioners as well as ... male and female childhood sexual survivors usually exhibit ... encounters with health care professionals, there are gender ...
... Mental health experts have said that New Orleans seems ... post-traumatic stress// disorder of an intensity rarely seen in ... that existed before hurricane Katrina struck, 10 months ago. ... has almost collapsed completely leaving the police department to ...
... Celiac Sprue Research Foundation have claimed to discover a ... is an inherited inflammatory disorder of the small intestine ... The two research studies that have been published in ... the way for clinical testing with an oral enzyme ...
... recalled almost around 20,000 chocolate bars in Britain as ... bars may contain traces of salmonella. ,A ... minute traces of salmonella, which though quite are significantly ... for any hazards. The spokesperson had also clarified that ...
... announced their plans to use a protein that has been ... ice creams using genetically// modified technology. ,The parent ... them to develop ice creams that are of low-calorie, and ... technology to make newer versions of their best selling products ...
Cached Medicine News:Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 2Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 3Health News:Sexually Abused Males Found Struggling In heir relations with Healthcare Providers 2Health News:Scientists Discover Non-dietary Therapy For Celiac Diseases 2Health News:Wall's To Develop Low-fat Ice-cream Using Fish Blood 2
The Mini Anchor is an exceptionally strong, versatile anchor. This anchor comes in either a load-your-own or QUICKANCHOR format, preloaded on either 2/0 or 0 ETHIBOND EXCEL suture with swaged needles...
... titanium alloy implants used for ... They are indicated where high ... SuperAnchor uses four Nitinol arcs ... small size. The unique design ...
The 4mm diameter Revo suture anchor is designed primarily for arthroscopic and open rotator cuff repair. Additional applications include other shoulder repair procedures, as well as use in knees and ...
The Linvatec UltraFix Suture Anchor System's smooth surface until deployed eliminates tissue, bone and suture damage and its ultra smooth eyelet hole preserves suture integrity....
Medicine Products: